ContraVir Pharma receives positive NASDAQ listing decision

The Nasdaq Hearings Panel granted ContraVir Pharmaceuticals’ (NASDAQ:CTRV) request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions.

In a statement, the company said it is working to achieve full compliance with all applicable requirements for continued listing.

ContraVir is focused on development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.